Polyiclc

Mesothelioma

Case Comprehensive Cancer CenterPhase 1/2Dormant

CC

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 73/ 100

Competitive context

62 Active assets in the Mesothelioma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide National Cancer Institute (NCI)	Phase 2	BB
Nivolumab Orion Corporation, Orion Pharma	Phase 2	B
Calcium folinate pentahydrate Amphia Hospital	Phase 4	B
Fludarabine National Cancer Institute (NCI)	Phase 2	B
Pembrolizumab Genmab	Phase 2	B

View all 50 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant

B

Indicative ·

63 / 100

melanomaDormant

B

Indicative ·

63 / 100

ocular melanomaDormant

B

Indicative ·

63 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.